SCHEMBL7658170

SCHEMBL7658170

Oc1nc2cc(-c3nc4cc(-c5nc6cc(Br)ccc6[nH]5)ccc4[nH]3)ccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 7/20 0.49
MMP2 P08253 6/20 0.49
MMP9 P14780 6/20 0.49
MMP8 P22894 6/20 0.49
HDAC6 Q9UBN7 2/20 0.43
PDPK1 O15530 1/20 0.41
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ATM Q13315 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8873633 0.87 NOS1 (0.41) MMP13MMP2MMP9MMP8PDPK1
SCHEMBL27236921 0.84 MMP2 (0.55) MMP13MMP2MMP9MMP8HDAC6
Iodide SCHEMBL27236940 0.83 MMP2 (0.54) MMP13MMP2MMP9MMP8HDAC6
SCHEMBL7654167 0.82 NPC1 (0.51) MMP13MMP2MMP9MMP8HDAC6
SCHEMBL20982568 0.80 MMP2 (0.57) MMP13MMP2MMP9MMP8HDAC6
SCHEMBL1170673 0.80 PDPK1 (0.51) MMP13MMP2MMP9MMP8PDPK1
SCHEMBL7652407 0.79 MMP13 (0.56) MMP13MMP2MMP9MMP8KDM4E
SCHEMBL3337505 0.78 ALDH1A1 (0.55) MMP13MMP2MMP9MMP8KDM4E
SCHEMBL6264476 0.78 MMP2 (0.77) MMP13MMP2MMP9MMP8KDM4E
SCHEMBL26753826 0.78 KDM4E (0.61) MMP13MMP2MMP9MMP8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6399642-B2 TRIS BENZIMIDAZOLES; FUNGICIDES, ANTICARCINOGENIC AGENTS, ENZYME INHIBITOR RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2002-06-04 US disclosed
US-20010009919-A1 Heterocyclic topoisomerase poisons RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2001-07-26 US disclosed
US-6221892-B1 Heterocyclic topoisomerase poisons THE STATE OF UNIVERSITY OF NEW JERSEY, RUTGERS 2001-04-24 US disclosed
EP-1054870-A1 HETEROCYCLIC TOPOISOMERASE POISONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2000-11-29 EP disclosed
US-6063801-A Heterocyclic topoisomerase poisons RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2000-05-16 US disclosed
WO-1999041241-A1 HETEROCYCLIC TOPOISOMERASE POISONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1999-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010009919-A1 Heterocyclic topoisomerase poisons TOP1, TOP2A, TOP2B MMP13 2829/4885MMP2 2263/4885MMP9 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.